Outcomes
breast cancer
BREAST CANCER
In the safety population (n = 104), the median relative dose intensity (defined as [actual dose intensity/planned dose intensity] × 100, where planned dose intensity [mg/day] = planned dose at Day 1) was 100% in all three treatment arms. Only one episode of dose modification was reported; this was due to participant error and occurred in the 200 mg arm. Three participants (one in the 200 mg arm and two in the 400 mg arm) had a total of four episodes of dose omission (one episode due to COVID-19, two because the participant forgot, and one unexplained). All participants underwent surgery for breast cancer as planned, between one and three days after the last dose of study medication. Ninety-two participants (88.5%) underwent surgery the day after their final dose.